AstraZeneca PLC AstraZeneca prices a $3bn bond issue (0063V)
04 Agosto 2020 - 01:00AM
UK Regulatory
TIDMAZN
RNS Number : 0063V
AstraZeneca PLC
04 August 2020
4 August 2020 07:00 BST
AstraZeneca prices a $3bn bond issue
AstraZeneca PLC announces that, on 3 August 2020, it priced a
three tranche global bond offering totalling $3bn. The offering is
expected to close on 6 August 2020, subject to customary closing
conditions. AstraZeneca expects to use the net proceeds of the
issue for general corporate purposes, which may include the
refinancing of existing indebtedness. The transaction, which is a
global offering registered with the US Securities and Exchange
Commission (SEC), consists of the following three tranches:
-- $1.2bn of fixed rate notes with a coupon of 0.700%, maturing 8 April 2026;
-- $1.3bn of fixed rate notes with a coupon of 1.375%, maturing 6 August 2030; and
-- $0.5bn of fixed rate notes with a coupon of 2.125%, maturing 6 August 2050.
BofA Securities, Inc., HSBC Securities (USA) Inc. and Mizuho
Securities USA LLC acted as joint book-running managers on the
transaction and Barclays Capital Inc., Citigroup Global Markets
Inc., Deutsche Bank Securities Inc., Goldman Sachs & Co. LLC,
J.P. Morgan Securities LLC and Morgan Stanley and Co. LLC acted as
co-managers on the transaction. The notes will be issued under
AstraZeneca's effective shelf registration statement on Form F-3,
which AstraZeneca filed with the SEC on 8 November 2019. The
offering is being made solely by means of the prospectus contained
within that shelf-registration statement, along with a prospectus
supplement forming part of the effective registration statement,
which investors should read.
A copy of the prospectus supplement and accompanying prospectus
relating to the offering can be obtained by contacting BofA
Securities, Inc. at 1-800-294-1322, HSBC Securities (USA) Inc. at
1-866-811-8049, or Mizuho Securities USA LLC at 1-866-271-7403.
Readers may also download these documents for free by visiting the
Electronic Data Gathering, Analysis, and Retrieval (EDGAR) system
on the SEC website at www.sec.gov .
This announcement shall not constitute an offer to sell or the
solicitation of an offer to buy the securities described herein,
nor shall there be any sale of these securities in any jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such jurisdiction.
The bond issuance does not impact the Company's financial
guidance for 2020.
About AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas -
Oncology, Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. For more information, please visit
astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Cautionary Statements Regarding Forward-Looking Statements
This announcement contains certain forward-looking statements
with respect to the operations, performance and financial condition
of AstraZeneca. Although the Company believes its expectations are
based on reasonable assumptions, any forward-looking statements, by
their very nature, involve risks and uncertainties and may be
influenced by factors that could cause actual outcomes and results
to be materially different from those predicted. The
forward-looking statements reflect knowledge and information
available at the date of preparation of this announcement and
AstraZeneca undertakes no obligation to update these
forward-looking statements.
Contacts
For details on how to contact the Investor Relations Team,
please click here. For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IODUOUURRVUWRUR
(END) Dow Jones Newswires
August 04, 2020 02:00 ET (06:00 GMT)
Astrazeneca (LSE:AZN)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Astrazeneca (LSE:AZN)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024